<DOC>
	<DOCNO>NCT02170714</DOCNO>
	<brief_summary>Background aim : Acute severe ulcerative colitis ( ASC ) potentially life-threatening event . Poor pediatric data available success rate Infliximab ( IFX ) second line therapy . This study perform consecutively observed pediatric patient ASC , treat accord 2011 European Crohn 's colitis Organization ( ECCO ) - European Society Pediatric Gastroenterology , Hepatology nutrition ( ESPGHAN ) guideline pediatric ASCÂ¹ aim ass long-term efficacy IFX clinical predictor poor outcome . Methods : Children hospitalize episode ASC , define Pediatric Ulcerative Colitis Activity Index ( PUCAI ) least 65 point , enrol . Clinical assessment PUCAI laboratory data ( Erythrocyte Sedimentation Rate , C-Reactive Protein , hemoglobin , albumin , hematocrit , ferritin ) record admission day 3 5 . All patient treat accord mention guideline ASC receive intravenous ( iv ) corticosteroid ( CS ) first-line therapy . IFX administer second-line therapy CS-refractory patient . In 2-year follow overall colectomy rate efficacy IFX avoid colectomy evaluate .</brief_summary>
	<brief_title>Efficacy Infliximab Rescue Therapy Pediatric Acute Severe Colitis</brief_title>
	<detailed_description />
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis ASC Confirmed diagnosis ulcerative colitis ( UC ) Age 118 year Not confirm diagnosis UC Contraindications infliximab therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Acute severe colitis</keyword>
	<keyword>Children</keyword>
	<keyword>Infliximab</keyword>
	<keyword>colectomy</keyword>
</DOC>